MedTrace Logo

Study in Healthy Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of VM-1500

NCT02489487 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2018-10-04

No results posted yet for this study

Summary

A randomized single dose, drug-drug interaction study in healthy volunteers for VM - 1500 given alone or in combination with Raltegravir or Darunavir in a 3 arm approach. The parallel design is used due to the long half life for VM-1500.

Conditions

  • HIV-infection

Interventions

DRUG

VM-1500

VM-1500 40 mg

DRUG

Darunavir

Darunavir 600 mg

DRUG

Ritonavir

Ritonavir 100 mg

DRUG

Raltegravir

400 mg Raltegravir

Sponsors & Collaborators

  • Viriom

    lead INDUSTRY

Principal Investigators

  • Somruedee Chatsiricharoenkul, MD · Acriles

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2014-10-31
Completion
2014-10-31

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02489487 on ClinicalTrials.gov